Molecular Approach to Cancer Management
Auteur : Sherbet Gajanan V.
Molecular Approach to Cancer Management discusses molecular mechanisms of cancer initiation, growth and secondary spread, emphasizing how this information can be used to devise new modes of treatment of cancer, especially in combatting secondary spread. The book addresses the basic concepts relating to cancer biology, the genetic determinants, and the signal transduction cascades associated with tumor growth, EMT, stem cell maintenance and propagation, and invasion and metastasis. The salient features of the signaling systems that are amenable to targeted manipulation are emphasized to facilitate research and development in the design of novel therapies and for the planning of new trials.
This book is the only unique volume with coverage of topics that target therapy. As such, it is a valuable source for cancer researchers, molecular oncologists and members of the biomedical field who are interested in knowing more about molecular approaches to cancer therapy.
1. Modulation of growth factor signaling in targeted therapy: Role of the epidermal growth factor family and their receptors2. The TGF-B family accessory type III receptor function in cancer progression3. Insulin-like growth factor signaling as a target to control tumor progression4. Angiogenesis in neoplasia and antiangiogenesis strategy in the control of tumor growth and metastasis5. On the trail of TRAIL in tumor growth and angiogenesis6. Hedgehog (Hh) signaling in EMT, CSCs and angiogenesis7. Hedgehog is involved in angiogenic signaling by angiopoietin-18. Hippo signaling in cell proliferation, migration and angiogenesis9. Tumor suppression and inhibition of angiogenesis by TXNIP10. Suramin and polysulphonated naphthylureas as angiogenesis inhibitors 11. Quercetin inhibits growth factor signaling: suppresses angiogenesis and cell migration in vitro12. Selenoproteins in cancer control13. Inhibitor of DNA binding proteins in angiogenesis14. Are there gains to be made in exploring anthrax lethal toxin (LeTx) as a tumor and an angiogenesis inhibitor?15. Small molecule inhibitors of angiogenesis and cell proliferation16. Control of tumor growth and angiogenesis by thalidomide and its analogues17. Endogenous inhibitors of angiogenesis18. Metformin and its antitumor attributes19. Statins in cancer biology20. The HMG (High mobility group) proteins in cancer progression21. MTAs in EMT activation and tumor and metastasis promotion22. S100A4 has potential benefits as a therapeutic target23. Notch Signaling in carcinogenesis24. Canonical and non-canonical activation of NF-?B in tumorigenesis25. Stem cells in cancer therapy26. Notable approaches to cancer immunotherapy
cancer researchers;oncologists;molecular oncologists
- Covers all relevant topics with a defined aim of targeted therapy
- Encompasses the basic aspects of cancer invasion and metastasis
- Discusses signaling systems operating in normal cells and their deregulation in cancer cells
- Directs attention to the foci in signaling systems that can be targeted with a new and conventional drug-based approach
Date de parution : 06-2017
Ouvrage de 352 p.
19x23.3 cm
Thème de Molecular Approach to Cancer Management :
Mots-clés :
14-3-3σ; A20/intracellular ubiquitin-editing protein; AICAR; AMPK; AMPK/LKB1; Agonistic death receptor antibodies; Allosteric inhibitors; Angiogenesis; Angiogenesis/VEGF; Angiomotins; Angiopoietins; Angiostatin; Anthrax lethal toxin; Anti-angiogenic agents; Anti-inflammation; Apoptosis; Apoptosis family genes; Apricoxib; Arrestins; BHLH proteins; Bcl gene family; Berenil; Betaglycan; Betaglycan-inhibin pathway; Bevacizumab; Bisphosphonate; Brain metastases; CD28 family; CSC biology; CSCs; Calcium-binding protein; Cancer invasion/metastasis; Cancer stem cell (CSC); Canonical and non-canonical signalling tumour progression endoglin; Canonical/non-canonical signalling; Celecoxib; Cell cycle; Cell motility invasion; Cell proliferation; Cell proliferation/survival; Cereblon; Chiral enantiomers; Chiral stability; Cholesterol synthesis; Collagen-derived inhibitors; Curcumin; Cyclopamine; Death receptors; Delta-like ligands; Distamycin; Drug conjugates EGFR/HER2 conjugates; Drug resistance; E-cadherin/β-catenin; EGF/EGFR/Akt; EMT; EMT activation; EMT activation/stem cells; EMT and stem cells; EMT/CSC; EMT/CSCs; ER; ER signalling; Endogenous angiogenesis inhibitors; Endogenous inhibitors of angiogenesis; Endostatin; Ets family transcription factors; FAK suppression; Flavonoids; Fumagillin hypomethylation; GLI inhibitors; Gadolinium nanoparticles; Genetic damage; Genistein; Growth factor receptor signalling; Growth factor receptors; Growth factors; HER2; HIF1/VEGF; HMG (high mobility group) A2; HMG proteins; HMGB1; Hedgehog; Hedgehog signalling; Hh/TGF-β/Wnt; Hippo/YAP/TAZ; IGF; IGFBP; IRS; Immune checkpoint proteins; Immune responses; Immune surveillance; Immunomodulation; Immunotherapy; Inhibitors of DNA-binding proteins (IDs); Inhibitory kringles; Invasion; Invasion/metastasis; Ipilimumab; Lethal factor; MAPK/38-ERK